Efficacy and Safety of Irinotecan Liposome Injection Combined With Oxaliplatin and Tegafur (NASOX) in Adjuvant Chemotherapy for Pancreatic Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• ECOG performance status 0 or 1.
• Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1).
• ECOG performance status 0 or 1.
• Life expectancy of greater than or equal to 6 months.
• Able and willing to provide a written informed consent.
Locations
Other Locations
China
FirstNanjingMU
RECRUITING
Nanjing
Contact Information
Primary
KuiRong Jiang, archiater
Jiangkuirong@163.com
15312995688
Time Frame
Start Date: 2024-04-08
Estimated Completion Date: 2028-07-31
Participants
Target number of participants: 53
Treatments
Experimental: Irinotecan liposome injection+ Oxaliplatin +Tegafur
Oxaliplatin: 60mg/m2, d1, ivgtt, 2h; Repeat every 15 days; Irinotecan liposomes: 50mg/m2, d1, ivgtt, 90min; Repeat every 15 days; Tegafur: 40-60mg, BID, po, d1-d10, repeat every 15 days; 30 days as one cycle, 6 treatment cycles.
Related Therapeutic Areas
Sponsors
Collaborators: CSPC Ouyi Pharmaceutical Co., Ltd.
Leads: Kuirong Jiang